Abstract |
The therapeutic efficacy of miocamycin against Ureaplasma urealyticum and Chlamydia trachomatis was the object of this study. Two different groups of patients were included in the trial: 40 males and 20 females affected by NGU and AUS respectively. All the patients positive for chlamydiae and/or ureaplasmas received 1200 mg/die of miocamycin for 12 days; a microbiological examination was performed 5 days from the end of the therapy. The therapy with miocamycin caused the resolution of both symptoms and microorganisms present. The use of miocamycin in current therapy could be favourable.
|
Authors | P M Furneri, L Roccasalva, L Fallica, G Tempera |
Journal | International journal of clinical pharmacology research
(Int J Clin Pharmacol Res)
Vol. 8
Issue 2
Pg. 111-6
( 1988)
ISSN: 0251-1649 [Print] Switzerland |
PMID | 3259948
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Acute Disease
- Chlamydia Infections
(drug therapy)
- Chlamydia trachomatis
- Female
- Genital Diseases, Female
(drug therapy)
- Genital Diseases, Male
(drug therapy)
- Humans
- Leucomycins
(pharmacology, therapeutic use)
- Male
- Miocamycin
- Mycoplasmatales Infections
(drug therapy)
- Syndrome
- Ureaplasma
- Urethral Diseases
(drug therapy)
- Urethritis
(drug therapy)
|